The 12-month safety and efficacy of pegloticase + methotrexate (MTX) in the MIRROR trial shows continued efficacy and tophi resolution after 12 months of therapy.
Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.
Dr. John Cush RheumNow
3 years 3 months ago
Commercial claims analysis of 21,044 pts w/ simultaneous B/L TKA vs 126,264 matched unilateral TKA. 90 day risk showed B/L TKA had signif more pulmonary embolism (aOR 2.13), CVA (2.21), acute anemia (2.06), transfusion (7.8), 90d readmission (1.35) https://t.co/ZW7fa3fbfC https://t.co/nVqRospVIV
Dr. John Cush RheumNow
3 years 3 months ago
JAMA: Prophylaxis for Pneumocystis Pneumonia - indications and Rx
- Immuncompromised and Immunodeficient
- Pts on Hi Dose Steroids
- ANCA–associated vasculitis
https://t.co/2VhLxc4VNo https://t.co/cXuY4Manrk
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?
https://t.co/nt4m6n27A3 https://t.co/oo88u5X86Z
Dr. John Cush RheumNow
3 years 3 months ago
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
https://t.co/MAjgWg71vK https://t.co/UhMtiWf7gh
Dr. John Cush RheumNow
3 years 3 months ago
Upadacitinib Outcomes in High Risk RA Patients
A safety analysis of six phase III SELECT trials showed that higher-risk RA patients had an increased risk of MACE, malignancy (excluding NMSC) and VTE regardless of being treated with either UPA or ADA.
https://t.co/7JXntIV09K https://t.co/CthPcu2Ohs
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Dr. John Cush RheumNow
3 years 3 months ago
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/NubTu8mGq4 https://t.co/OQSIpHgLyn
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
https://t.co/SLgUKQKbFs https://t.co/xCc2D5Hx8S
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: 25 Great Women in Rheumatology
https://t.co/ghCAUBMMja https://t.co/cr2xI2VrgE
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting
A trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSI or NS as the initial treatment.
https://t.co/b8yZSKRK2X https://t.co/zOYaYOtuJd
Dr. John Cush RheumNow
3 years 3 months ago
Pain is the leading cause of disability worldwide. Chronic pain affects 33-50% of the population. High impact chronic pain is seen in 4.8% of US adult population. Chronic pain accounts for 22-50% of GP consultations. More from BMJ.. https://t.co/IRVpJZNS0L https://t.co/YVIM38aWWK
Dr. John Cush RheumNow
3 years 3 months ago
Full read review of "Treatments for Lupus Nephritis" from Isenberg et al - discussing:
- Pathogenesis, outcomes
- Conventional Rx
- B cell targeting: BEL, RTX, Obintuzumab, Atacicept & more
- Sequential Rx: Synviose, BEAT, BLISS-Believe
- JAKi & more https://t.co/X0xn9FeL0j https://t.co/Fiyf5Drh93
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
